Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23095392 | 1.00 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL8031100 | 0.85 | ALDH1A1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL25947506 | 0.85 | ALDH1A1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL20807998 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL20132733 | 0.80 | TAS1R3 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL20715990 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL20206293 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL24603042 | 0.77 | TAS1R3 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4TAS1R3 | |
| SCHEMBL23336220 | 0.76 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL19890610 | 0.76 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | CHRNB2 4093/4885CHRNB4 4157/4885CHRNA3 4132/4885 |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CHRNB2 4140/4885CHRNB4 4425/4885CHRNA3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.